MedImmune, L.L.C.
Overview
MedImmune works to boost the immune systems of babies and grown-ups. Its flagship biotech product, Synagis, prevents respiratory syncytial virus (RSV), a major cause of pneumonia and other respiratory disease in infants and children. Also on the market are FluMist, its nasal spray flu vaccine, and Ethyol, which treats side effects of chemotherapy and radiation. The company is working on dozens of investigational therapies -- including monoclonal antibodies, vaccines, and small molecule drugs -- in the areas of infectious diseases, cancer, and inflammatory conditions. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for MedImmune, L.L.C.
| Company Type | Subsidiary of AstraZeneca |
|---|---|
| Fiscal Year-End | December |
Key People from Hoover's UK
Key people and executives for MedImmune, L.L.C.
| President | Peter S. Greenleaf (Subscribers see complete biographies -- view sample)
|
|---|---|
| EVP Operations | Bernardus N.M. (Ben) Machielse |
| EVP and CFO | Tim Pearson |
Top Competitors from Hoover's UK
Top competitors of MedImmune, L.L.C.
There are 25 competitors for MedImmune; see more.
